ScreenerHero

DNTHDianthus Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · dianthustx.com
111.10USD-2.29%Mkt Cap: 6.07B $P/E: —

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal ant…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Zacks
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
Simply Wall St.
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
Stocktwits
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Investor's Business Daily
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Barchart
Stocks Resume Decline as Chipmakers and AI Companies Fall
Barchart
Stocks Fall on Weakness in Tech and Trucking Companies
Barchart
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative
Simply Wall St.
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
IInsider Monkey
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier

Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc (NASDAQ:DNTH) stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials. In the safety update, the FDA has dropped antinuclear antibodies as […]

IInsider Monkey